MMED Stock — MiniMed Group, Inc.

MiniMed Group, Inc. (MMED)

Updated October 16, 2026.

MMED is a Stock. Total return is -12.6% over the past 0.6 years, 25.5 points behind SPY at 12.9%.

MiniMed Group, Inc. is a medical technology company that develops, manufactures, and markets diabetes management equipment, including insulin pumps, continuous glucose monitors, automated insulin delivery systems, and related software platforms. The company serves people with diabetes requiring insulin therapy and operates as a subsidiary of Medtronic plc. Distribution information for this security is not currently available.

MMED performance versus SPY

Price and return data through 2026-10-16.

Total return is -12.6% over the past 0.6 years, 25.5 points behind SPY at 12.9%.

MMED key facts

Asset type

Stock

Asset class

Equity

Inception date

03/05/2026

Distribution frequency

None

Last close

$17.49 (as of 2026-10-16)

Market cap

$4,920,810,293

Average volume

21451439.0

Payout ratio

0.0%

Forward P/E

26.0202

EPS

$-1.53

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MMED risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider MMED — and who may not

It is a weaker fit for investors who need monthly cash flow (MMED does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MMED

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions